255 results about "Human cell" patented technology

The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and / or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and / or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides a variety of configurations of the RNA prime editors each comprising a nucleic acid programmable RNA binding proteins (napRNAbp), such as Cas13, and an RNA-dependent RNA polymerase (RDRP), which are provided as fusion proteins or which can be separately provided in trans. The RNA prime editors are guided to a target RNA site by a guide RNA, which can be a rpegRNA that includes a template region for the synthesis of an RNA sequence to be installed on the RNA molecule attached to an available 3′ terminus. In others embodiments, the RNA template can be provided in trans.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

The present invention relates to a hybrid exosome formed by the fusion of a human cell-derived exosome and an artificial exosome. When an active ingredient labeled with a fluorescent material was attached or encapsulated in the hybrid exosome of the present invention and applied to cells, the active ingredient was observed in the cells. In addition, when the exosome was applied to skin tissue, fluorescence expression could also be observed in the dermal layer. Therefore, the hybrid exosome according to the present invention can be used as a novel drug delivery system.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The present invention relates to recellularization of xenogeneic tissue. Specifically, the present invention relates to recellularization of xenogeneic tissue, which enables transplantation of non-immunogenic biological tissue with improved durability and regenerative capacity by generating xenogeneic tissue having regenerative capacity through human cell recellularization after removal of galactose-alpha-1,3-galactose (α-Gal) xenoantigens and non-galactose (non-Gal) xenoantigens.

The present invention provides a human T cell lacking human leukocyte antigen (HLA) class I molecule and containing an exogenous ST6GALNAC6 gene, which has the following characteristics (a) and / or (b):(a) CD62L-positive and CD45RA-positive(b) a total ATP production rate of a human T cell-containing cell population of 400 pmol / min / 105 cells or more and a mitochondrial spare respiratory capacity of 40 pmol / min / 105 cells or more, 5-6 days after the application of T cell proliferation stimulation to the cell population. According to the present invention, a low-immunogenic human T cell that can remain stably in the body for a long period of time after transplantation is provided, and the development of a versatile CAR-T cell or TCR-T cell for allotransplantation becomes possible by using the human T cell.

Systems and methods for highly-effective CRISPR-Cas based genomic editing within human chromosome 15q11-q13 have been developed as therapeutic interventions for Angelman Syndrome (AS). Selective single guide RNA molecules (sgRNAs) that impart enhanced CRISPR-Cas editing of genomic mutations associated with Angelman Syndrome in human cells are described. The engineered sgRNAs induce activity of non-pathogenic, paternal UBE3A alleles to reduce, reverse and / or prevent the causative neurodevelopmental defects of AS in a subject in need thereof. Compositions and methods of engineered crRNAs, sgRNAs thereof and ribonucleoprotein (RNP) complexes thereof are provided for enhanced genomic engineering with increased on-off target specificity and on-target editing efficacy for treatment of AS.

The present invention is a precursor crRNA for a type I CRISPR-Cas system having a modified nucleotide, in which at least one nucleotide is a modified nucleotide in a region comprising the 5'arm region of a first repeat sequence, the 5 '-side stem formation region of the first repeat sequence, and the ring formation region of the first repeat sequence.

Provided herein, inter alia, are compositions for treating Human T-cell lymphotropic virus type 1 (HTLV-1) associated diseases. The compositions include a protein having a zinc finger domain capable of binding a sequence within an HTLV-1 long terminal repeat (LTR). Further provided are methods of treating HTLV-1 associated diseases in a subject in need thereof. The methods include administering to the subject the protein including the zinc finger domain, or a nucleic acid encoding the protein.

A composition is provided comprising a cell population and pharmaceuticals derived from human gingival fibroblasts, present in proportions not found in natural gingival tissue, but having a cellular phenotype preferentially selected to express proteins favorable for angiogenesis and anti-inflammatory effects, while reducing the formation of cell populations that promote tumorigenesis and / or metalloproteinases that inhibit tissue regeneration. A method for producing such a composition that increases proliferation several times over compared to previously known methods is provided, and a method for using such a composition in a wide range of human cell therapies is also provided.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

To provide a gene modified cell including a modified T cell receptor (TCR) alpha steady region gene in a genome of the gene modified cell.SOLUTION: There is provided a gene modified cell including in a genome thereof, a modified human T cell receptor (TCR) alpha steady region gene, the modified human TCR alpha steady region gene includes, from 5' to 3', a 5' region of the human TCR alpha steady region gene, an exogenous polynucleotide, and a 3' region of the human TCR alpha steady region gene. The modified human TCR alpha steady region gene is a gene modified human T cell or a gene modified cell derived from a human T cell, and in comparison with a non-modified control cell, expression of an endogenous TCR on a cell surface is suppressed.SELECTED DRAWING: Figure 1

We have discovered that allogeneic HSC-engineered human iNKT (3rdHSC-iNKT) cells display potent anti-GvHD functions, by eliminating antigen-presenting myeloid cells in vitro and in xenograft models, without negatively impacting tumor eradication by allogeneic T cells in preclinical models of lymphoma and leukemia. The 3rdHSC-iNKT cells closely resembled the CD4−CD8− / + subsets of endogenous human iNKT cells in phenotype and functionality. Embodiments of the invention harness these discoveries in new methods and materials for alleviating graft versus host disease.

This document discloses compositions for use with engineered human cells, the compositions comprising a cell regulator or a carrier encoding a cell regulator. This document describes compositions comprising engineered cells, wherein the engineered cells are engineered human cells and contain modifications that make the engineered cells more resistant to alkylating drugs or nucleoside analogs compared to non-engineered human cells. Various methods for treating diseases are provided, including methods for treating cancer in a subject by administering cell regulators and / or engineered cells as therapeutic agents.

The present invention refers to a novel and efficient method for large-scale selective generation of yδ T cells, preferably human Vδ1+yδ T cells, optimal for clinical application in adoptive immunotherapy of cancer. In this sense, considering that both human cord blood HPCs, currently elected as source of stem cells in the clinic, and human early thymic progenitors can efficiently generate de novo human yδ T cells in response to Notch signalling, and most efficiently in response to the Notch ligand Jag2, the method thus comprises inducing the differentiation of cord blood CD34+ hematopoietic progenitor cells (HPCs) and / or human CD34+ early thymic progenitors, by activating them with Jag2 Notch ligands.

The invention discloses nutrient liquid for supplementing energy to human cells and a preparation method of the nutrient liquid, and belongs to the field of functional foods and beverages. The preparation method comprises the following steps: equivalently mixing fructus hippophae, longan pulp, Chinese dates, Chinese wolfberry fruits, mulberries, malt, raspberries and honey, sealing and fermenting, and filtering to obtain an active enzyme a stock solution; mixing Chinese yam, hawthorn, wheat, cinnamon, mulberry leaf, emblic leafflower fruit, kelp, momordica grosvenori, honeysuckle, kudzuvine root, rhizoma polygonati, black sesame, houttuynia cordata, purslane, dandelion, lucid ganoderma, ginseng, American ginseng, dogwood, eucommia ulmoides leaf and cistanche according to an equal amount to obtain a fermentation base material, mixing the fermentation base material with the active enzyme a stock solution, performing anaerobic fermentation, and performing low-temperature drying to obtain enzyme b; the stock solutions of the enzyme b and the active enzyme a are mixed, cooked and filtered to obtain mixed juice, a unique formula raw material is developed, and the nutrient solution with the good dissolved oxygen content is obtained through the sealed fermentation technology and the anaerobic fermentation technology.

The present invention belongs to the field of antibody technology, and in particular relates to monoclonal antibodies, antibody conjugates and applications thereof against p21 proteins. The amino acid sequences of the complementary determining regions CDR1-3 on the light chain variable region of the monoclonal antibody are shown as SEQ ID NO.3-5, respectively; the amino acid sequences of the complementary determining regions CDR1-3 on the heavy chain variable region are shown as SEQ ID NO.8-10, respectively. The monoclonal antibody provided by the present invention can specifically recognize p21 proteins expressed by human cells and tissues, has good affinity for binding to p21 proteins, high recognition sensitivity, and strong anti-interference ability, is suitable for immunodiagnostic analysis of p21 proteins in tissues / cells, and has broad application prospects and good market prospects in clinical diagnosis and scientific research detection. In addition, the antibody has cross-reactivity to homologous p21 proteins of humans, rats and mice, and has certain applicability to the detection of rat and mouse p21 proteins.

Provided herein are genetically modified rodent models of disease, wherein the rodent expresses at least an antigen presenting portion of a classical human leukocyte antigen (HLA) molecule, and comprises, in its periphery, human T cells, e.g., engineered human T cells genetically modified to express at least a recombinant human T cell receptor (TCR) variable domain that binds an antigen presented in the context of the antigen presenting portion of the HLA. Also provided herein are methods of making and using the same, e.g., for identifying therapeutic candidates for treatment of a disorder associated with an HLA-peptide-TCR interaction.

The invention belongs to the technical field of health drinks, and particularly relates to an agilawood capsule and a preparation method thereof. The agilawood leaf capsule overcomes the defect of insufficient absorption of effective components in a traditional agilawood leaf tea brewing and drinking mode, the agilawood leaves are reasonably treated and prepared into capsule dosage forms, so that a user can more conveniently, stably and efficiently take in the effective components in the agilawood leaves, and the effects of resisting oxidation, reducing blood sugar and blood fat, relieving constipation and the like of the agilawood leaf capsule are fully exerted. The adamantane-modified pullulan can be more easily taken and absorbed by human cells, and when the adamantane-modified pullulan is prepared into a capsule shell, the physiological activity of effective components in the agilawood leaf tea powder can be better exerted, and the absorption efficiency is improved.

The present application relates to the field of cosmetic technology, and more particularly to a full-link whitening and freckle-removing liposome and a preparation method thereof, the liposome comprising the following components: an aqueous phase, a membrane material and an oil phase. In the preparation process, 4-butyl resorcinol, nonapeptide-1, acetylchitosamine and ascorbic acid tetraisopalmitate are combined to form a full-link effect of signal inhibition-synthesis blockage-blocked conversion-metabolic acceleration, and a multi-target whitening and freckle-removing system is constructed. In addition, tranexamic acid, hydrolyzed yeast protein and schizophyllan are combined to synergistically make the finished product have excellent soothing and moisturizing effects. Furthermore, the finished product is prepared into a liposome capable of encapsulating active ingredients, which effectively improves the stability of the active ingredients, prevents their oxidation and inactivation, and the liposome structure is highly similar to the human cell membrane, is easy to penetrate the keratin layer gap, realizes targeted delivery to the deep layer of the epidermis, and makes the active ingredients truly act on the required site.

Provided are methods for treating pancreatic cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

The invention discloses a bra with microporous polyurethane cups and a preparation method thereof, and relates to the field of high polymer materials, the bra comprises a bra body frame, and the pair of microporous polyurethane cups is mounted on the bra body frame; according to the bra with the microporous polyurethane cups and the preparation method of the bra, the prepared bra with the microporous polyurethane cups has moisture absorption and quick-drying performance and far infrared performance, sweat moisture excreted by a human body can be instantly absorbed, transmitted and diffused to the outer surface of the bra and quickly evaporated and dried, a good skin metabolism environment is provided, and the bra is dry and comfortable without stuffiness when worn; and the far infrared radiation generated by a human body can be absorbed and reflected, resonance with human cells is realized, blood circulation is promoted, and the far infrared physiotherapy device is suitable for auxiliary physiotherapy of hyperplasia of mammary glands and breast distending pain and discomfort, can be washed by hands and machines and is long in service life.

The present disclosure relates to methods of producing engineered human cells. Methods may comprise providing a composition for inducing a modification of a target endogenous nucleic acid sequence in a nucleus of a human cell, wherein the composition comprises an amount of a Cas9 protein and an amount of a sgRNA in an in vitro environment free of the human cell. In some embodiments, the amount of sgRNA and the amount of Cas9 protein may be present in the composition at a weight ratio of 4:9 to 4:3. A Cas9 / sgRNA complex may form in the in vitro environment prior to being introduced into the human cell. Methods may further comprise introducing the Cas9 / sgRNA complex into the human cell via electroporation, wherein the Cas9 / sgRNA complex induces the modification of the target endogenous nucleic acid sequence in the nucleus of the human cell.

The present invention relates to a phage-based gene delivery system targeting human cells or animal cells, including immune cells, other human cells and cancer cells. In particular, the present invention relates to novel phage particles and associated phagemid expression systems and their production for the delivery of transgenes, comprising DNA encoding pathogen antigens, to human immune cells, suitable for use in vaccines and vaccine development against infectious diseases and cancers.

Non-human animals (and / or non-human cells) and methods of using and making the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Ig light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.